Biomarker-driven clinical trials for anti-cancer drug development

被引：0
|
作者：
Kim, Dong-Wan [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS12-3
引用
收藏
页码：1703 / 1703
页数：1
相关论文
共 50 条
  • [1] BIOMARKER-DRIVEN TRIALS IN EARLY DRUG DEVELOPMENT
    Fine, B. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 22 - 22
  • [2] Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
    Tan, Daniel S. W.
    Thomas, George V.
    Garrett, Michelle D.
    Banerji, Udai
    de Bono, Johann S.
    Kaye, Stan B.
    Workman, Paul
    CANCER JOURNAL, 2009, 15 (05): : 406 - 420
  • [3] From drug discovery to biomarker-driven clinical trials in lymphoma
    Younes, Anas
    Berry, Donald A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (11) : 643 - 653
  • [4] From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Donald A. Berry
    Nature Reviews Clinical Oncology, 2012, 9 : 643 - 653
  • [5] Ethical Challenges in Biomarker-Driven Drug Development
    Hey, Spencer Phillips
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (01) : 23 - 25
  • [6] Biomarker-driven patient selection for early clinical trials
    Dienstmann, Rodrigo
    Rodon, Jordi
    Tabernero, Josep
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 305 - 312
  • [7] STRATIFICATION AND PARTIAL ASCERTAINMENT OF BIOMARKER VALUE IN BIOMARKER-DRIVEN CLINICAL TRIALS
    Simon, Richard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (05) : 1011 - 1021
  • [8] PNC is a biomarker for anti-cancer drug development.
    Huang, S.
    MOLECULAR BIOLOGY OF THE CELL, 2023, 34 (02) : 162 - 162
  • [9] The inverted pyramid of biomarker-driven trials
    Ignacio Garrido-Laguna
    Manuel Hidalgo
    Razelle Kurzrock
    Nature Reviews Clinical Oncology, 2011, 8 : 562 - 566
  • [10] The inverted pyramid of biomarker-driven trials
    Garrido-Laguna, Ignacio
    Hidalgo, Manuel
    Kurzrock, Razelle
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (09) : 562 - 566
12345